All In MedTech

Device Trial Radar · NCT07322913

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry

Post-Market Clinical Follow-up Registry to Evaluate the Safety and Performance of the Intervascular Vascular Grafts and Patches in Patients Undergoing Bypass, Replacement, or Repair of Aortic, Peripheral, or Carotid Arteries

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
IntervascularNot on our public-company list
Sponsor type
Industry
First posted
Jan 7, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this registry is to evaluate the long-term safety and performance of Intervascular Vascular Grafts and Patches (Intergard Standard, Hemashield, Intergard Silver, Intergard Synergy) for bypass, repair or replacement of aortic, peripheral, or carotid arteries. This registry is intended to further define the expected product lifetime of the devices and to collect data related to usefulness of the antimicrobial coatings.

Conditions

  • Carotid Artery Diseases
  • Aortic Diseases
  • Peripheral Arterial Diseases

Interventions

  • Intergard Standard - Collagen Coated Vascular Grafts and PatchesDevice

    Intergard Standard, Collagen coated vascular grafts and patches are made of knitted (knitted or knitted ultrathin) or woven polyester. The products are coated with a highly purified form of cross-linked bovine collagen to minimize intraoperative bleeding and eliminate the need for preclotting at the time of implant. Note that the radially supported grafts have a polypropylene supportive coil designed to resist kinking and compression of extra-anatomical vascular repair, where potential unwanted mechanical compression of the graft may occur.

  • Hemashield - Collagen Coated Vascular Grafts and PatchesDevice

    Hemashield Vascular Grafts and Patches are made of knitted or woven polyester. The products are impregnated with a highly purified bovine collagen to reduce bleeding at the time of implant and thereby eliminates the operative preclotting step.

  • Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and PatchesDevice

    Intergard Silver antimicrobial collagen coated vascular grafts are made of knitted (knitted or knitted ultrathin) or woven polyester. The Hemapatch Silver Ultrathin is a surgical patch made from knitted ultrathin polyester fabric. The products are coated with a highly purified form of cross-linked bovine collagen to minimize intraoperative bleeding and eliminate the need for preclotting at the time of implant. In addition to collagen coating, the collagen matrix of Intergard Silver vascular grafts and patches is loaded with an antimicrobial agent: silver acetate. The coating of silver is designed to inhibit the microbial colonization on the device and within tissue immediately proximate to the device in the acute post-operative phase.

  • Intergard Synergy - Antimicrobial Collagen Coated Vascular GraftsDevice

    Intergard Synergy antimicrobial collagen coated vascular grafts are made of knitted (knitted or knitted ultrathin) polyester. The products are coated with a highly purified form of cross-linked bovine collagen to minimize intraoperative bleeding and eliminate the need for preclotting at the time of implant. In addition to collagen coating, the collagen matrix of Intergard Synergy Antimicrobial collagen coated vascular grafts is loaded with antimicrobial agents: silver acetate and triclosan. The addition of silver acetate and triclosan on collagen coated vascular products is designed to inhibit the microbial colonization on the device and in the surrounding tissues in the acute postoperative phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peripheral Arterial Disease Cohort: Cohort: Percentage of participants meeting primary device patencyTime frame: Procedure/surgery through registry completion, anticipated average of 5 years
  2. Aortic Disease Cohort: Percentage of participants meeting primary device patencyTime frame: Procedure/surgery through registry completion, anticipated average of 5 years
  3. Carotid Artery Disease Cohort: Percentage of participants achieving freedom from occlusion or reinterventionTime frame: Procedure/surgery through registry completion, anticipated average of 5 years

4 more outcomes with a free account

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • The Pennsylvania State University and The Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.